Research programme: engineered HIV vaccines - The Scripps Research Institute/International AIDS Vaccine Initiative/La Jolla Institute for Allergy and Immunology

Drug Profile

Research programme: engineered HIV vaccines - The Scripps Research Institute/International AIDS Vaccine Initiative/La Jolla Institute for Allergy and Immunology

Alternative Names: eOD GT8 60mer

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator International AIDS Vaccine Initiative; La Jolla Institute for Allergy & Immunology; The Scripps Research Institute
  • Developer International AIDS Vaccine Initiative; La Jolla Institute for Allergy & Immunology; Rockefeller University; The Scripps Research Institute
  • Class AIDS vaccines; Protein-vaccines
  • Mechanism of Action B cell stimulants; Immunogenetic stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 24 Mar 2016 The Scripps Research Institute, International AIDS Vaccine Initiative and La Jolla Institute for Allergy and Immunology are planning a phase I trial for HIV infections in USA
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top